Voice of China at EBMT 2026 | Professor Shan Fu: Ultra-Low Dose Achieves 91.7% Complete Remission—IL-10 CAR-T Therapy Demonstrates the Potential of “Enhanced Efficacy with Reduced Dose”

Voice of China at EBMT 2026 | Professor Shan Fu: Ultra-Low Dose Achieves 91.7% Complete Remission—IL-10 CAR-T Therapy Demonstrates the Potential of “Enhanced Efficacy with Reduced Dose”

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
Voice of China at EBMT | Professor Yanmin Zhao: Pre-Transplant Genetic MRD Monitoring Improves Risk Stratification in TP53-Mutated AML/MDS

Voice of China at EBMT | Professor Yanmin Zhao: Pre-Transplant Genetic MRD Monitoring Improves Risk Stratification in TP53-Mutated AML/MDS

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
Voice of China at EBMT | Dr. Jingjing Feng: Dual-Target CD19/BCMA CAR-T Therapy Opens New Hope for Neuromyelitis Optica Spectrum Disorder

Voice of China at EBMT | Dr. Jingjing Feng: Dual-Target CD19/BCMA CAR-T Therapy Opens New Hope for Neuromyelitis Optica Spectrum Disorder

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
Professor Ming Hou: From “Following” to “Leading”—Key Updates in the 2025 Chinese Guidelines for Adult Immune Thrombocytopenia

Professor Ming Hou: From “Following” to “Leading”—Key Updates in the 2025 Chinese Guidelines for Adult Immune Thrombocytopenia

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and immunology, the meeting highlighted cutting-edge developments and evolving clinical strategies.
Professor Xiaohui Zhang: Building on 25 Years of Progress—Advancing High-Quality Development in Hematologic Immunology

Professor Xiaohui Zhang: Building on 25 Years of Progress—Advancing High-Quality Development in Hematologic Immunology

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026, coinciding with the 25th anniversary of the Hematology and Immunology Branch of the Chinese Society of Immunology.
Professor Hongmei Jing: From Nature Breakthroughs to Clinical Practice—Advances in Precision Diagnosis and Treatment of Lymphoma

Professor Hongmei Jing: From Nature Breakthroughs to Clinical Practice—Advances in Precision Diagnosis and Treatment of Lymphoma

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and immunology, the meeting highlighted cutting-edge developments and evolving clinical strategies.
Professor Zonghong Shao：Immune Dysregulation in Myelodysplastic Syndromes and Clinical Management Strategies

Professor Zonghong Shao：Immune Dysregulation in Myelodysplastic Syndromes and Clinical Management Strategies

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and immunology, the meeting highlighted cutting-edge developments and evolving clinical strategies.
Professor Junmin Li: Exploration and Clinical Practice of Umbilical Cord Blood Therapy in Elderly Patients with Acute Myeloid Leukemia

Professor Junmin Li: Exploration and Clinical Practice of Umbilical Cord Blood Therapy in Elderly Patients with Acute Myeloid Leukemia

In March, as spring brings clarity and renewal to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was convened from March 27 to 28, 2026, marking the 25th anniversary of the Hematology and Immunology Branch of the Chinese Society of Immunology.
Professor Zhenyu Yan: Seven Transformations in the Comprehensive Management of Hemophilia in China — From Survival to Functional Cure

Professor Zhenyu Yan: Seven Transformations in the Comprehensive Management of Hemophilia in China — From Survival to Functional Cure

In March, as spring breathes new life into Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, organized by the Hematology and Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was successfully convened from March 27 to 28, 2026. During the meeting, Professor Zhenyu Yan from the Affiliated Hospital of North China University of Science and Technology delivered a keynote lecture entitled “Seven Transformations in the Comprehensive Diagnosis and Management of Hemophilia in China.”